Literature DB >> 15358652

Differential immune responses to primary measles-mumps-rubella vaccination in Israeli children.

Bracha Rager-Zisman1, Elina Bazarsky, Agneta Skibin, Guy Tam, Shlomo Chamney, Ilana Belmaker, Iris Shai, Ella Kordysh, Diane E Griffin.   

Abstract

Measles remains an important cause of morbidity and mortality worldwide, primarily due to problems associated with delivery of the live attenuated vaccine to susceptible populations. In some developed countries, there is concern about the effects of immunization on the immune system. In this study, we analyzed the responses of 12-month-old Bedouin and Jewish children living in Israel to routine measles-mumps-rubella (MMR) vaccination. Seroconversion to measles was 99% in Bedouin and 79% in Jewish children (P < 0.01), and that to mumps and rubella was 92 to 100% in both groups. Measles neutralizing antibody titers were higher in Bedouin (333 +/- 39 mIU/ml) than Jewish (122 +/- 60 mIU/ml) children (P < 0.002). Immunoglobulin G levels were higher in Bedouin than Jewish children (P = 0.007) and increased after vaccination (P = 0.0009). Leukocyte (P < 0.02) and lymphocyte (P = 0.04) counts were higher and CD4 lymphocyte percentages were lower (P < 0.001) in Bedouin than Jewish children before and after vaccination. Leukocyte counts and natural killer cell numbers did not change after vaccination, but lytic activity increased in Bedouin children (P < 0.005). Spontaneous proliferation of cultured peripheral blood mononuclear cells increased with vaccination, but there were no changes in the proliferative responses to phytohemagglutinin or tetanus toxoid. In summary, no adverse effects of MMR vaccination on immune function were detected. However, there were differences in underlying immunologic parameters and in response to the measles component of the vaccine between Bedouin and Jewish children. It is not known whether genetic differences or environmental exposure accounts for these differences.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15358652      PMCID: PMC515267          DOI: 10.1128/CDLI.11.5.913-918.2004

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  32 in total

1.  Twin studies of immunogenicity--determining the genetic contribution to vaccine failure.

Authors:  P L Tan; R M Jacobson; G A Poland; S J Jacobsen; V S Pankratz
Journal:  Vaccine       Date:  2001-03-21       Impact factor: 3.641

2.  Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial.

Authors:  A Dilraj; F T Cutts; J F de Castro; J G Wheeler; D Brown; C Roth; H M Coovadia; J V Bennett
Journal:  Lancet       Date:  2000-03-04       Impact factor: 79.321

3.  Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age.

Authors:  M Ceyhan; G Kanra; G Erdem; B Kanra
Journal:  Vaccine       Date:  2001-08-14       Impact factor: 3.641

4.  The 1st International Standard for anti-measles serum.

Authors:  T Forsey; A B Heath; P D Minor
Journal:  Biologicals       Date:  1991-07       Impact factor: 1.856

5.  Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age.

Authors:  J Klinge; S Lugauer; K Korn; U Heininger; K Stehr
Journal:  Vaccine       Date:  2000-07-15       Impact factor: 3.641

6.  Immune modulation after measles vaccination of 6-9 months old Bangladeshi infants.

Authors:  J J Schnorr; F T Cutts; J G Wheeler; S M Akramuzzaman; M S Alam; T Azim; S Schneider-Schaulies; V ter-Meulen
Journal:  Vaccine       Date:  2001-01-08       Impact factor: 3.641

7.  Identification of an association between HLA class II alleles and low antibody levels after measles immunization.

Authors:  G A Poland; I G Ovsyannikova; R M Jacobson; R A Vierkant; S J Jacobsen; V S Pankratz; D J Schaid
Journal:  Vaccine       Date:  2001-11-12       Impact factor: 3.641

8.  Associations between human leukocyte antigen homozygosity and antibody levels to measles vaccine.

Authors:  Jennifer L St Sauver; Inna G Ovsyannikova; Robert M Jacobson; Steven J Jacobsen; Robert A Vierkant; Daniel J Schaid; V Shane Pankratz; Erin M Green; Gregory A Poland
Journal:  J Infect Dis       Date:  2002-05-09       Impact factor: 5.226

9.  Differential CD4 T cell activation in measles.

Authors:  D E Griffin; B J Ward
Journal:  J Infect Dis       Date:  1993-08       Impact factor: 5.226

10.  Functional and phenotypic changes in circulating lymphocytes from hospitalized zambian children with measles.

Authors:  Judith J Ryon; William J Moss; Mwaka Monze; Diane E Griffin
Journal:  Clin Diagn Lab Immunol       Date:  2002-09
View more
  6 in total

1.  Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunized.

Authors:  Kazutoyo Miura; Hong Zhou; Ababacar Diouf; Gregory Tullo; Samuel E Moretz; Joan A Aebig; Michael P Fay; Louis H Miller; Ogobara K Doumbo; Issaka Sagara; Alassane Dicko; Carole A Long; Ruth D Ellis
Journal:  Vaccine       Date:  2011-01-31       Impact factor: 3.641

Review 2.  Genetic studies of African populations: an overview on disease susceptibility and response to vaccines and therapeutics.

Authors:  Giorgio Sirugo; Branwen J Hennig; Adebowale A Adeyemo; Alice Matimba; Melanie J Newport; Muntaser E Ibrahim; Kelli K Ryckman; Alessandra Tacconelli; Renato Mariani-Costantini; Giuseppe Novelli; Himla Soodyall; Charles N Rotimi; Raj S Ramesar; Sarah A Tishkoff; Scott M Williams
Journal:  Hum Genet       Date:  2008-05-30       Impact factor: 4.132

3.  Prevalence of antibodies against measles, mumps and rubella in the childhood population in Singapore, 2008-2010.

Authors:  L W Ang; F Y Lai; S H Tey; J Cutter; L James; K T Goh
Journal:  Epidemiol Infect       Date:  2012-09-24       Impact factor: 4.434

4.  Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized, Controlled Trial in Guinea-Bissau.

Authors:  Vu An Do; Sofie Biering-Sørensen; Ane Bærent Fisker; Carlito Balé; Stine Møller Rasmussen; Lone Damkjær Christensen; Kristoffer Jarlov Jensen; Cesário Martins; Peter Aaby; Christine Stabell Benn
Journal:  J Infect Dis       Date:  2017-04-15       Impact factor: 5.226

5.  Prevalence of Maternal Measles Antibody and Its Associated Factors among Infants in Coastal Karnataka, India.

Authors:  S Sathiyanarayanan; Pawan Kumar; Chythra R Rao; Arun Kumar; Asha Kamath; Veena Kamath
Journal:  Indian J Community Med       Date:  2020 Jan-Mar

6.  A randomized trial of an early measles vaccine at 4½ months of age in Guinea-Bissau: sex-differential immunological effects.

Authors:  Kristoffer Jarlov Jensen; Mia Søndergaard; Andreas Andersen; Erliyani Sartono; Cesario Martins; May-Lill Garly; Jesper Eugen-Olsen; Henrik Ullum; Maria Yazdanbakhsh; Peter Aaby; Christine Stabell Benn; Christian Erikstrup
Journal:  PLoS One       Date:  2014-05-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.